Taysha Gene Therapies (TSHA) Enterprise Value (QoQ) (2020 - 2026)

Taysha Gene Therapies (TSHA) Enterprise Value (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Taysha Gene Therapies 2.14 Bn 2.14 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 13.48%
Dec 31, 2025 -7.53%
Sep 30, 2025 4.92%
Jun 30, 2025 -167.60%
Mar 31, 2025 16.09%
Dec 31, 2024 11.79%
Sep 30, 2024 8.69%
Jun 30, 2024 -39.19%
Mar 31, 2024 13.82%
Dec 31, 2023 12.11%
Sep 30, 2023 -264.39%
Jun 30, 2023 28.92%
Sep 30, 2022 44.23%
Jun 30, 2022 33.27%
Mar 31, 2022 34.58%
Dec 31, 2021 20.73%
Sep 30, 2021 3.02%
Jun 30, 2021 13.69%
Mar 31, 2021 8.98%
Dec 31, 2020 9.83%